

EBMT SURVEY ON TRANSPLANT ACTIVITY 2014- CIC:Team 0916

Table 1: Report the total number of patients receiving their 1st allogeneic and/or 1st autologous transplant in your centre in 2014 according to indication, donor type and stem cell source.

Table 2: Report all other 'non first' transplants here. **Table 3:** Report the total number of NMA and DLI's here.

Table 4: Report any HSC/MSCT therapies here and on the separate cellular therapy survey.

Help with reporting your data can be found in the guidelines.


 Table 1		NUMBER OF PATIENTS RECEIVING FIRST TRANSPLANTS ONLY IN 2014															Total allo after auto			
		Allogeneic									Autologous			Total						
		HLA - id sibling			Family			Twin			Unrelated							Allo	Auto	Total
		BM	PBSC	Cord	BM	PBSC	Cord	BM	PBSC	Cord	BM	PBSC	Cord	BM	PBSC	Cord				
Leukemias	AML 1st CR		7											1			11	3	14	
	non 1st CR		4											2						
	ALL 1st CR		8																11	
	non 1st CR		3																	
	CML 1st cP																			
	not 1st cP																			
	MDS or MD/MPN		1																1	
MPN																				
CLL incl. PLL																				
LPD	PCD - Myeloma													33				33	33	
	PCD - other																			
	HD													30					30	
	NHL													7					7	
Solid tumors	Neuroblastoma																			
	Soft tissue sarcoma																			
	Germ cell tumors																			
	Breast Cancer																			
	Ewing													1					1	
	Other solid tumors																			
Non - Malignant disorders	BM aplasia - SAA		1														1	1		
	BM aplasia - other		1														1	1		
	Hemoglob. - thalassemia		2														2	2		
	Hemoglob. - sickle cell																			
	Primary Immune deficiencies																			
	Inh. disorders of metabolism		1														1	1		
	Auto immune disease																			
Others																		102		
TOTAL 1st Transplants																				
Number pediatric patients: age <18 at transplant																				

Table 2: Non 1st transplants performed in 2014

Retransplants	2														
Additional transplants															
TOTAL All Transplants	2														

Table 3: Additional Information for the transplants reported in Table 1 and 2.

Number of Non-Myeloablative transplants performed in 2014	25
---	----

Number of patients receiving DLI infusions in 2014	3
--	---

Table 4: Cellular therapies

Number of Patients receiving Hematopoietic Cells for non hematopoietic use in 2014	ALLO		AUTO		
	ALLO	AUTO	ALLO	AUTO	
Cardiovascular			Number of Patients receiving Mesenchymal Stromal Cells (MSC) in 2014	GvHD prevention/treatment	2
Neurological				HSC graft enhancement	2
Tissue repair / musculoskeletal				Other (please specify)	
Epithelial				Please also report this data on the separate more detailed survey on novel cell therapies/tissue engineering. Contact H. Baldomero if you require one.	